These 2 companies are high-risk investments, but they nonetheless have the potential to become pivotal players in the rapidly expanding field of immuno-oncology. Here’s why.
These 2 companies are high-risk investments, but they nonetheless have the potential to become pivotal players in the rapidly expanding field of immuno-oncology. Here’s why.